Fibroblast growth factor modulates mast cell recruitment in a murine model of prostate cancer
Metrics: PDF 1717 views | HTML 1936 views | ?
Roberto Ronca1, Roberto Tamma2,3, Daniela Coltrini1, Simona Ruggieri2, Marco Presta1 and Domenico Ribatti2,3
1Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
2Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy
3National Cancer Institute “Giovanni Paolo II”, Bari, Italy
Domenico Ribatti, email: [email protected]
Marco Presta, email: [email protected]
Keywords: angiogenesis, fibroblast growth factor-2, long pentraxin-3, mast cell, prostate cancer
Received: June 15, 2017 Accepted: June 28, 2017 Published: August 01, 2017
Mast cells are important modifiers of prostate tumor microenvironment. The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) system plays a non-redundant autocrine/paracrine role in the growth, vascularization and progression of prostate tumors. Accordingly, the FGF antagonist long pentraxin-3 (PTX3) and the PTX3-derived small molecule FGF-trap NSC12 have been shown to inhibit the growth and vascularization of different FGF-dependent tumor types, including prostate cancer. In this study, we show that recombinant FGF2 is able to cause mast cell recruitment in vivo in the Matrigel plug assay. Conversely, PTX3 overexpression in transgenic mice or treatment with the FGF inhibitor NSC12 result in a significant inhibition of the growth and vascularization of TRAMP-C2 tumor grafts, a murine model of prostate cancer, that were paralleled by a decrease of mast cell infiltrate into the lesion. These data confirm and extend previous observations about the capacity of mast cells to respond chemotactically to FGF2 stimulation and provide evidence about a relationship among mast cell recruitment, angiogenesis, and tumor growth in human prostate adenocarcinoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.